For: | Tamaki K, Okubo A. Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: First case report. World J Gastroenterol 2015; 21(3): 1009-1013 [PMID: 25624738 DOI: 10.3748/wjg.v21.i3.1009] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i3/1009.htm |
Number | Citing Articles |
1 |
|
2 |
Yu Jun Wong, Si Yuan Chew, John Chen Hsiang, Prem Harichander Thurairajah, Rahul Kumar, Eng Kiong Teo, Roshni Sadashiv Gokhale, Imran Bin Mohamed Noor, Jessica Tan. VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature. Clinical and Molecular Hepatology 2019; 25(2): 218 doi: 10.3350/cmh.2018.0017
|
3 |
Peginterferon-α-2a/ribavirin/simeprevir. Reactions Weekly 2015; 1539(1): 229 doi: 10.1007/s40278-015-7784-4
|
4 |
Richard A. Helmers, Thomas J. Byrne, Lewis J. Wesselius, Kevin O. Leslie. Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient. Mayo Clinic Proceedings 2015; 90(9): 1294 doi: 10.1016/j.mayocp.2015.06.015
|
5 |
D. Banerjee, K. R. Reddy. Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapy. Alimentary Pharmacology & Therapeutics 2016; 43(6): 674 doi: 10.1111/apt.13514
|
6 |
Takahiro Kamada, Kenjiro Furuta, Hiromi Tomioka. Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report. Respiratory Investigation 2016; 54(3): 207 doi: 10.1016/j.resinv.2015.12.003
|
7 |
Syeda Zainab Ilyas, Rabia Tabassum, Haroon Hamed, Shafiq Ur Rehman, Ishtiaq Qadri. Hepatitis C Virus-Associated Extrahepatic Manifestations in Lung and Heart and Antiviral Therapy-Related Cardiopulmonary Toxicity. Viral Immunology 2017; 30(9): 633 doi: 10.1089/vim.2017.0009
|
8 |
Cristina Scavone, Liberata Sportiello, Concetta Rafaniello, Annamaria Mascolo, Maurizio Sessa, Francesco Rossi, Annalisa Capuano. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opinion on Drug Safety 2016; 15(sup2): 85 doi: 10.1080/14740338.2016.1221396
|